Edwards Lifesciences (EW) Tops Q2 EPS by 8c; Lifts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Edwards Lifesciences Reports Second Quarter Results
July 28, 2015 4:01 PM EDTIRVINE, Calif., July 28, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended June 30, 2015 of $112.7 million, or $1.02 per diluted share. Adjusted net income on a non-GAAP basis was $124.4 million, or $1.13 per diluted share, compared to $0.88 per diluted share in the prior year period. In the year ago period, GAAP net income was $5.09 per diluted share, which included a $750 million payment to Edwards from a litigation... More



